Kairos Pharma is a clinical-stage biopharmaceutical company focused on cancer immunotherapy and drug resistance.
Kairos Pharma has raised $75.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in January 2026.
Kairos Pharma's investors include U.S. Department of War, Congressionally Directed Medical Research Programs.
Kairos Pharma is headquartered in Los Angeles, United States.
Kairos Pharma is a clinical-stage biopharmaceutical company focused on cancer immunotherapy and drug resistance.
Kairos Pharma is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kairos Pharma — Funding & Investors." VCBacked, January 12, 2026, https://www.vcbacked.co/company/kairos-pharma. Accessed August 15, 2026.
VCBacked. (2026). Kairos Pharma — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/kairos-pharma
{{cite web |title=Kairos Pharma — Funding & Investors |url=https://www.vcbacked.co/company/kairos-pharma |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated